帶狀皰疹藥物市場規模、佔有率、成長分析（按診斷、治療和預防、按給藥途徑、按最終用戶、按地區）—產業預測 2025-2032

2023 年全球帶狀皰疹藥物市場規模為 22 億美元，預計將從 2024 年的 24.2 億美元成長到 2032 年的 51.9 億美元，預測期內（2025-2032 年）的複合年成長率為 10.0%。

帶狀皰疹治療市場持續成長，主要原因是老年族群中帶狀皰疹的發生率不斷上升。人們對帶狀皰疹後遺症神經痛預防措施和管理的認知不斷提高，推動了對疫苗和抗病毒治療的需求。技術創新，尤其是人工智慧，正在徹底改變研究方向，促進候選藥物的快速識別，並改善患者的治療效果。專注於提高長期免疫力的疫苗臨床試驗正在增加，尤其是在醫療保健條件改善的發展中地區。然而，儘管帶狀皰疹的發生率不斷上升，但新型療法的研發管道仍然有限，積極研發的公司寥寥無幾。重組帶狀皰疹疫苗因其持久的療效和較低的副作用而廣受好評，其應用也為市場發展勢頭做出了積極貢獻。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

帶狀皰疹治療藥物市場規模（按診斷和複合年成長率）（2025-2032）

• 市場概覽
• 實驗室測試
• 螢光顯微鏡
• 即時聚合酵素鏈鎖反應（PCR）
• 血清學檢測
• 其他

帶狀皰疹藥物市場規模（依治療及預防）及複合年成長率（2025-2032）

• 市場概覽
• 抗病毒藥物
• 藥品
• 抗發炎藥物
• 抗組織胺藥
• 抗驚厥藥
• 辣椒素
• 麻醉霜、凝膠和貼片
• 疫苗
• 其他

帶狀皰疹藥物市場規模（按給藥途徑和複合年成長率） (2025-2032)

• 市場概覽
• 口服
• 外用
• 其他

帶狀皰疹治療藥物市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 醫院和診所
• 診斷中心
• 研究和學術機構
• 居家照護環境
• 其他

帶狀皰疹治療藥物市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• GlaxoSmithKline（GSK）（UK）
• Merck & Co., Inc.（USA）
• Pfizer Inc.（USA）
• Sanofi（France）
• Novartis AG（Switzerland）
• Astellas Pharma Inc.（Japan）
• ModernaTX, Inc.（USA）
• Dynavax Technologies Corporation（USA）
• Curevo, Inc.（USA）
• Jiangsu Recbio Technology Co., Ltd.（China）
• Luzhu Biotechnology Co., Ltd.（China）
• Green Cross Corporation（South Korea）
• BioNTech（Germany）
• Bristol-Myers Squibb（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• SK bioscience（South Korea）
• Vaxine Pty Ltd（Australia）
• EpiVax（USA）
• Virios Therapeutics（USA）
• WEX Pharmaceuticals Inc.（Canada）

結論和建議

Global Herpes Zoster Therapeutics Market size was valued at USD 2.2 billion in 2023 and is poised to grow from USD 2.42 billion in 2024 to USD 5.19 billion by 2032, growing at a CAGR of 10.0% during the forecast period (2025-2032).

The herpes zoster therapeutics market is witnessing consistent growth, largely fueled by the increasing prevalence of shingles in an aging population. A surge in awareness regarding preventive measures and the management of post-herpetic neuralgia is driving demand for vaccines and antiviral treatments. Innovations in technology, particularly AI, are revolutionizing research, facilitating rapid drug candidate identification and enhancing patient outcomes. Clinical trials focused on vaccines that improve long-term immunity are on the rise, especially in developing regions with improved healthcare access. However, the pipeline for new therapies remains limited, with few companies actively pursuing development despite the growing incidence of herpes zoster. The adoption of recombinant zoster vaccines, celebrated for their lasting efficacy and reduced side effects, is also contributing positively to market momentum.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Herpes Zoster Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Herpes Zoster Therapeutics Market Segments Analysis

Global Herpes Zoster Therapeutics Market is segmented by Diagnosis, Treatment and Prevention, Route of Administration, End User and region. Based on Diagnosis, the market is segmented into Laboratory Testing, Immunofluorescent Microscopy, Real-Time Polymerase Chain Reaction (PCR), Serological Testing and Others. Based on Treatment and Prevention, the market is segmented into Antiviral Medications, Narcotic Medications, Anti-Inflammatory Medications, Antihistamines, Anticonvulsants, Capsaicin, Numbing Creams, Gels, or Patches, Vaccines and Others. Based on Route of Administration, the market is segmented into Oral, Topical and Others. Based on End User, the market is segmented into Hospitals & Clinics, Diagnostic Centers, Research & Academic Institutes, Home Care Settings and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Herpes Zoster Therapeutics Market

The Global Herpes Zoster Therapeutics market is being propelled by advancements in Artificial Intelligence, which are enhancing drug discovery processes. Cutting-edge algorithms are adept at sifting through extensive datasets, encompassing genetic, proteomic, and chemical compound libraries, to pinpoint promising antiviral candidates. This innovation significantly lowers both the cost and duration of preclinical and clinical development phases. By 2024, major pharmaceutical companies, such as Pfizer, alongside emerging biotech firms, have adopted AI-driven platforms to expedite research efforts. As a result, this integration is fostering the swift development of next-generation vaccines and treatments for shingles and related complications, including post-herpetic neuralgia (PHN).

Restraints in the Global Herpes Zoster Therapeutics Market

The global market for herpes zoster therapeutics faces significant constraints due to the stringent regulatory frameworks and data privacy issues surrounding the use of patient information for artificial intelligence (AI) algorithm training. In jurisdictions with strict health data protection regulations, such as the General Data Protection Regulation (GDPR) in Europe, the integration of AI in clinical settings is slowed considerably. These regulatory challenges can result in delays for AI-driven innovations, consequently impeding the growth of the market. Consequently, the potential benefits of AI in enhancing herpes zoster therapeutics may be stifled by these compliance-related obstacles.

Market Trends of the Global Herpes Zoster Therapeutics Market

The Global Herpes Zoster Therapeutics market is witnessing a significant trend towards the integration of personalized artificial intelligence (AI) models for preventing post-herpetic neuralgia (PHN), a debilitating complication following shingles. These AI-driven approaches analyze various patient-specific factors, including immune response, genetic predispositions, and individual pain thresholds to formulate customized treatment regimens. By employing real-world data, companies like Tempus and IBM Watson Health are enhancing the efficacy of therapeutic interventions, leading to improved patient outcomes. This trend underscores a shift towards precision medicine, driving growth and innovation in the herpes zoster therapeutics landscape as healthcare evolves to meet personalized patient needs.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Herpes Zoster Therapeutics Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Laboratory Testing
• Immunofluorescent Microscopy
• Real-Time Polymerase Chain Reaction (PCR)
• Serological Testing
• Others

Global Herpes Zoster Therapeutics Market Size by Treatment and Prevention & CAGR (2025-2032)

• Market Overview
• Antiviral Medications
• Narcotic Medications
• Anti-Inflammatory Medications
• Antihistamines
• Anticonvulsants
• Capsaicin
• Numbing Creams, Gels, or Patches
• Vaccines
• Others

Global Herpes Zoster Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Topical
• Others

Global Herpes Zoster Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Diagnostic Centers
• Research & Academic Institutes
• Home Care Settings
• Others

Global Herpes Zoster Therapeutics Market Size & CAGR (2025-2032)

• North America (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • US
  • Canada
• Europe (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GlaxoSmithKline (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ModernaTX, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynavax Technologies Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curevo, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Recbio Technology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luzhu Biotechnology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SK bioscience (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxine Pty Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EpiVax (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virios Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WEX Pharmaceuticals Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations